LON:N4P

N4 Pharma Share Forecast, Price & News

GBX 9.45

0.00 (0.00 %)

(As of 02/26/2021 04:28 PM ET)

Add

Compare

Today's Range

9.10

Now: GBX 9.45▼

9.80

50-Day Range

7.50

MA: GBX 8.96▼

12.60

52-Week Range

Now: GBX 9.45▼

Volume719,513 shs

Average Volume3.85 million shs

Market Capitalization£17.11 million

P/E RatioN/A

Dividend YieldN/A

BetaN/A

N4 Pharma Plc, a specialist pharmaceutical company, develops and licenses novel therapeutic products pharmaceutical and biotechnology companies in the United Kingdom. It reformulates marketed generic drugs; and improves delivery of novel and existing vaccines and therapeutics. The company is developing Sildenafil for use in treating erectile dysfunction; Sartans for the treatment of hypertension; Aprepitant for use in oncology and pain relief; and Aprepitant for the treatment of premature ejaculation. It is also developing Nuvec, an engineered silica nanoparticle for use in intracellular delivery of large nucleic acids, such as pDNA and mRNA; and Single dose Hepatitis B vaccine. The company has a research collaboration with MedImmune to explore the manufacture of a prototype nanomedicine using its Nuvec system; and Nanomerics Limited to produce and test two candidate formulations using the Nuvec delivery system. N4 Pharma Plc is based in London, the United Kingdom.

Headlines

N4 Pharma PLC
January 23, 2021 | cnbc.com

How Much Did N4 Pharma's (LON:N4P) CEO Pocket Last Year?
November 23, 2020 | finance.yahoo.com

UBA Gross Earnings Hits N454.4Bn, Delivers NN90.4Bn PBT in Q3
November 22, 2020 | msn.com

IB Plc posts N4.6bn sales increase in Q3
November 22, 2020 | msn.com

N4 Pharma Plc Regulatory News
November 5, 2020 | lse.co.uk

Is N4 Pharma Plc's (LON:N4P) CEO Pay Fair?
May 26, 2020 | finance.yahoo.com

BRIEF-N4 Pharma Signs Research Collaboration With Nanomerics
February 11, 2020 | www.reuters.com

N4 Pharma Plc Share Chat
January 1, 2020 | www.lse.co.uk

Those Who Purchased N4 Pharma (LON:N4P) Shares A Year Ago Have A 71% Loss To Show For It
December 23, 2019 | finance.yahoo.com

Here's Why We're A Bit Worried About N4 Pharma's (LON:N4P) Cash Burn Situation
September 24, 2019 | finance.yahoo.com

N4 Pharma Plc Share Price (N4P)
September 11, 2019 | www.lse.co.uk

N4 Pharma Plc Share Chat (N4P)
July 4, 2019 | www.lse.co.uk

See More Headlines

Industry, Sector and Symbol

Stock Exchange LON

Industry Drug Manufacturers - Major

Sub-IndustryN/A

SectorMedical

Current SymbolLON:N4P

Previous Symbol

CUSIPN/A

CIKN/A

Webwww.n4pharma.com

Phone+44-1332-690061

Employees5

Year FoundedN/A

Debt

Debt-to-Equity Ratio1.62

Current Ratio22.63

Quick Ratio22.63

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales£23,524.00

Price / Sales727.43

Cash FlowGBX 2.24 per share

Price / Cash Flow4.23

Book ValueGBX 2.30 per share

Price / Book4.11

Profitability

EPS (Most Recent Fiscal Year)N/A

Net IncomeN/A

Net MarginsN/A

Return on EquityN/A

Return on AssetsN/A

Miscellaneous

Outstanding Shares181,080,000

Market Cap£17.11 million

Next Earnings DateN/A

OptionableNot Optionable

MarketRank^™

Overall MarketRank^™

0.48 out of 5 stars

0.0 Analyst's Opinion

Consensus Rating
There is not enough analysis data for N4 Pharma.

2.4 Community Rank

Outperform Votes
N4 Pharma has received 103 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
N4 Pharma has received 109 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
N4 Pharma has received 51.42% “underperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about N4 Pharma and other stocks. Vote “Outperform” if you believe N4P will outperform the S&P 500 over the long term. Vote “Underperform” if you believe N4P will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
N4 Pharma does not currently pay a dividend.
Dividend Growth
N4 Pharma does not have a long track record of dividend growth.

0.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, N4 Pharma insiders have not sold or bought any company stock.

0.0 Earnings and Valuation

Price to Earnings Ratio vs. the Market
The P/E ratio of N4 Pharma is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of N4 Pharma is -9.30, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Book Value per Share Ratio
N4 Pharma has a P/B Ratio of 4.04. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.

See Top Rated MarketRank™ Stocks Here

GBX 9.45

0.00 (0.00 %)

(As of 02/26/2021 04:28 PM ET)

30 days | 90 days | 365 days | Advanced Chart

Receive N4P News and Ratings via Email

Sign-up to receive the latest news and ratings for N4P and its competitors with MarketBeat's FREE daily newsletter.

N4 Pharma (LON:N4P) Frequently Asked Questions

What stocks does MarketBeat like better than N4 Pharma?

Wall Street analysts have given N4 Pharma a "N/A" rating, but there may be better short-term opportunities in the market. Some of MarketBeat's past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new trading ideas, but N4 Pharma wasn't one of them. MarketBeat thinks these five stocks may be even better buys.
View MarketBeat's top stock picks here.

How were N4 Pharma's earnings last quarter?

N4 Pharma Plc (LON:N4P) announced its quarterly earnings data on Thursday, September, 17th. The company reported ($0.48) earnings per share (EPS) for the quarter.
View N4 Pharma's earnings history.

How has N4 Pharma's stock price been impacted by COVID-19?

N4 Pharma's stock was trading at GBX 2.75 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization. Since then, N4P stock has increased by 243.6% and is now trading at GBX 9.45.
View which stocks have been most impacted by COVID-19.

Who are N4 Pharma's key executives?

N4 Pharma's management team includes the following people:

Mr. Nigel James Theobald, Founder, CEO & Director (Age 57, Pay $70k)
Dr. David Templeton, Part-Time Exec. Director & Technical Director
Mr. Luke Sebastian Cairns, Exec. Director (Age 43, Pay $24k)
Rob Harris, Head of CMC Devel.
Dr. Andrew Leishman, Consultant

Who are some of N4 Pharma's key competitors?

Some companies that are related to N4 Pharma include Sareum Holdings plc (SAR.L) (SAR), Futura Medical (FUM), Avivagen Inc. (VIV.V) (VIV), Cathay International Holdings Limited (CTI.L) (CTI), Antisense Therapeutics (ANP), Bayer Aktiengesellschaft (BAYN), Mayne Pharma Group (MAYNF), Mayne Pharma Group (MYX), Medical Developments International (MVP), Opthea (OPT), Otsuka (OTSKY), Patrys (PAB), Pharmaxis (PXS), Recce Pharmaceuticals (RCE) and Roche (RHHVF).
View all of N4P's competitors.

What other stocks do shareholders of N4 Pharma own?

Based on aggregate information from My MarketBeat watchlists, some companies that other N4 Pharma investors own include Intercede Group plc (IGP.L) (IGP), Medpace (MEDP), Regeneron Pharmaceuticals (REGN), Sirius Minerals (SXX), SolGold (SOLG), Reach plc (RCH.L) (RCH), Petra Diamonds (PDL), Interserve (IRV), Cornerstone Capital Resources Inc. (CGP.V) (CGP) and Bushveld Minerals (BMN).

What is N4 Pharma's stock symbol?

N4 Pharma trades on the London Stock Exchange (LON) under the ticker symbol "N4P."

How do I buy shares of N4 Pharma?

Shares of N4P and other U.K. stocks can be purchased through online brokerage accounts that support trading on the London Stock Exchange (LSX). Some U.K. companies can be purchased through major U.S. brokerages in the form of American Depository Receipts (ADRs), which are placeholder equities held in a trust by a bank that represent shares of a foreign stock.
Compare Top Brokerages Here.

What is N4 Pharma's stock price today?

One share of N4P stock can currently be purchased for approximately GBX 9.45.

How much money does N4 Pharma make?

N4 Pharma has a market capitalization of £17.11 million and generates £23,524.00 in revenue each year.

How many employees does N4 Pharma have?

N4 Pharma employs 5 workers across the globe.

What is N4 Pharma's official website?

The official website for N4 Pharma is www.n4pharma.com.

Where are N4 Pharma's headquarters?

N4 Pharma is headquartered at Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom.

How can I contact N4 Pharma?

N4 Pharma's mailing address is Weston House, 1 Bradgate Park View, DERBY, DE73 5UJ, United Kingdom. The company can be reached via phone at +44-1332-690061.

This page was last updated on 3/1/2021 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Best-in-Class Portfolio Monitoring
View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.
Stock Ideas and Recommendations
Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.
Advanced Stock Screeners and Research Tools
Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here